1차 출처 기록
결정급탑라인 결과
Immunic: ENSURE Phase 3 vidofludimus calcium의 RMS top-line 데이터는 2026년 말까지 예상
회사는 relapsing multiple sclerosis에서 vidofludimus calcium의 twin Phase 3 ENSURE-1 및 ENSURE-2 시험의 top-line 데이터가 2026년 말까지 예상된다고 발표했습니다. 이 readout은 다음 주요 규제 catalyst이며 2027년 중반에 계획된 NDA 제출에 정보를 제공할 것입니다.
핵심 사실
출처 발췌
EX-99.1 2 e665186_ex99-1.htm Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update – Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – – Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization – NEW YORK, February 26, 2026 – Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financ